Recent research suggests that medications commonly used to treat erectile dysfunction (ED) may also help reduce one’s risk of developing Alzheimer’s disease. This revelation comes from a large study conducted at University College London in the United Kingdom, which tracked the health records of about 270,000 men over several years.
The primary focus of this study was on phosphodiesterase type 5 (PDE5) inhibitors, a class of drugs that includes sildenafil (Viagra), tadalafil (Cialis), vardenafil (Levitra), and avanafil (Stendra). These medications are well-known for their ability to treat ED by enhancing blood flow, but they also have potential benefits for cardiovascular and cognitive health.
The present study included 269,725 men with a new diagnosis of erectile dysfunction between 2000 and 2017. Those with a prior history of cognitive impairment or dementia were excluded to ensure a more accurate assessment of Alzheimer’s risk. The average age of participants at the start of the study was 58.5 years, and the median follow-up period was 5.1 years. During this time, 1,119 men were newly diagnosed with Alzheimer’s disease.
A total of 749 men who used PDE5 inhibitors developed Alzheimer’s, translating to an incident rate of 8.1 per 10,000 person-years at risk. In contrast, 370 men who did not use these drugs were diagnosed with Alzheimer’s, with an incident rate of 9.7 per 10,000 person-years.
Over the median follow-up period, men who began using PDE5 inhibitors showed a significant reduction in their likelihood of receiving an Alzheimer’s diagnosis compared to those who did not use these drugs. Specifically, the researchers found that men on PDE5 inhibitors had a 18% lower risk of Alzheimer’s disease, indicating a hazard ratio of 0.82.
In medical research, a “hazard ratio” (HR) is a measure used to compare the risk of a certain event happening at any given point in time between two groups. Therefore, in the context of this study, an HR of 0.82 means that the group taking PDE5 inhibitors had an 18% lower risk of developing Alzheimer’s compared to the group not taking the drugs. An HR less than 1 shows a reduced risk, while an HR greater than 1 indicates an increased risk.
Interestingly, the protective effect of PDE5 inhibitors appeared to be dose-dependent. Men who had more than 20 prescriptions for these medications exhibited even greater reductions in Alzheimer’s risk. The individuals with 21 to 50 prescriptions of these medications had a hazard ratio of 0.56, and those with more than 50 prescriptions had a hazard ratio of 0.65.
The potential cognitive benefits of PDE5 inhibitors are also supported by animal studies, where sildenafil has been shown to improve memory and cognitive function, enhance synaptic plasticity (i.e., the adaptability of the connections between neurons in the brain), and reduce amyloid plaques, which are associated with Alzheimer’s. Tadalafil has also demonstrated similar effects in animal trials. However, translating these findings to humans is still a challenge, and more research is needed to confirm these benefits in clinical settings.
One of the limitations noted in the study is the reliance on electronic health records and insurance claims data, which may reflect an underdiagnosis or misdiagnosis of dementia. While the findings are promising, the data must be interpreted with caution due to potential biases in diagnosis and classification.
Given these limitations, there is a need for additional studies to explore the underlying mechanisms of PDE5 inhibitors in reducing Alzheimer’s risk. The authors of this study emphasized that a well-designed randomized controlled trial is necessary to establish a causal relationship and consider PDE5 inhibitors as a potential preventive measure for Alzheimer’s disease.
References:
Adesuyan, M., Jani, Y. H., Alsugeir, D., Howard, R., Ju, C., Wei, L., & Brauer, R. (2024). Phosphodiesterase type 5 inhibitors in men with erectile dysfunction and the risk of Alzheimer disease: A cohort study. Neurology, 102(4). https://doi.org/10.1212/WNL.0000000000209131
Brauer, R., et al. (2024). Erectile dysfunction drugs tied to less Alzheimer’s risk. Neurology. Retrieved from MedPage Today. https://www.medpagetoday.com/neurology/dementia/108626
You may also be interested in...
SMSNA Patients
Understanding Wearable Male Sexual Devices: Trends, Safety, and Benefits for Erectile Dysfunction
September 24, 2024Did You Know?
What Is the Typical Recovery Process After Inflatable Penile Prosthesis Surgery?
October 1, 2024SMSNA Patients
Early Trauma May Be Linked to Hypersexual Behavior and Erectile Dysfunction in Men
August 20, 2024SMSNA Patients
The Intersection of Telemedicine and Men’s Health
May 7, 2024Did You Know?
Do ED Medications Increase One’s Risk of Vision Problems?
May 3, 2022SMSNA Patients
How Affordable Are Erectile Dysfunction Treatments Around the World?
March 8, 2022Other Popular Articles
What Is Jelqing, and Does It Actually Work?
The term “jelqing” refers to a set of penis stretching exercises that some believe can make the penis bigger. Although the practice has gained attention and popularity in blogs and internet forums in recent years, there is no scientific evidence that it is an effective way to permanently increase the size of one’s penis. In fact, in some cases, jelqing may actually cause damage to the penis, so it is a good idea to get all the facts before setting off to try it.
What Is Sensate Focus and How Does It Work?
Sensate focus is a technique used to improve intimacy and communication between partners around sex, reduce sexual performance anxiety, and shift away from ingrained, goal-oriented sexual patterns that may not be serving a couple.
What Is the Average Penis Size?
If you have ever wondered how your penis compares to others in terms of size, you are not alone. Many men are curious to know how their penises stack up compared to the average. Unfortunately, general curiosity can sometimes give way to full-on obsession and anxiety about penis size. This can be an unhealthy and often unnecessary fixation, especially because most men who think their penises are too small have perfectly normal-sized penises.
What Is Edging and Why Do People Do It?
Edging is the practice of stopping sexual stimulation before reaching orgasm to prolong a sexual experience. The term stems from the concept of approaching the metaphorical “edge” of orgasm but stopping before going over the edge.
Can Sex Reduce Menstrual Cramps?
The SMSNA periodically receives and publishes ‘guest editorials.’ The current article was submitted by Mia Barnes, a freelance writer and researcher who specializes in women's health, wellness, and healthy living. She is the Founder and Editor-in-Chief of Body+Mind Magazine.
Having sex while you experience menstrual cramps is healthy and can provide significant benefits. While it might not be the first activity that comes to mind when your PMS or period cramping begins, many people enjoy sex to reduce menstrual cramps, experience increased pleasure and benefit from other advantages. Learn more about having sex while menstrual cramps are happening and how it can help your body.
The Sex-Positivity Movement: What it Means to Be Sex-Positive
You may have heard references to “being sex-positive” or “the sex-positivity movement” in popular culture. Various celebrities have brought attention to this movement by speaking out about their beliefs and personal experiences regarding sexuality, sexual health, body positivity, “slut-shaming,” and sexual assault.
